JPH07101817A - Curable composition for dental use - Google Patents

Curable composition for dental use

Info

Publication number
JPH07101817A
JPH07101817A JP6146972A JP14697294A JPH07101817A JP H07101817 A JPH07101817 A JP H07101817A JP 6146972 A JP6146972 A JP 6146972A JP 14697294 A JP14697294 A JP 14697294A JP H07101817 A JPH07101817 A JP H07101817A
Authority
JP
Japan
Prior art keywords
fine particles
parts
dental
paste
calcium phosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP6146972A
Other languages
Japanese (ja)
Inventor
Hiroko Wachi
和知  浩子
Takao Tanaka
隆夫 田中
Toshihiko Nishitsuji
俊彦 西辻
Yoshihito Ochiai
良仁 落合
Koichi Saito
浩一 斉藤
Fumio Osato
文夫 大里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lion Corp
Mitsui Toatsu Chemicals Inc
Original Assignee
Lion Corp
Mitsui Toatsu Chemicals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lion Corp, Mitsui Toatsu Chemicals Inc filed Critical Lion Corp
Priority to JP6146972A priority Critical patent/JPH07101817A/en
Publication of JPH07101817A publication Critical patent/JPH07101817A/en
Pending legal-status Critical Current

Links

Landscapes

  • Dental Preparations (AREA)

Abstract

PURPOSE:To provide a curable composition for dental use, having excellent fluidity in the form of paste and enabling the filling to a narrow or complicate- formed part such as root canal. CONSTITUTION:This curable composition for dental use contains calcium phosphate and a fluorine compound in combination with fine particles of a polymer.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、歯科用に用いる組成物
に関する。更に詳しくは、本発明は、優れた生体親和性
を持ち、歯の根管部やその他の骨欠損部及び骨空隙部を
充填できる自己硬化型歯科用組成物に関する。
FIELD OF THE INVENTION The present invention relates to a dental composition. More specifically, the present invention relates to a self-hardening dental composition having excellent biocompatibility and capable of filling root canal portions of teeth, other bone defects and bone voids.

【0002】[0002]

【従来の技術】従来、歯科用組成物としては、例えば、
リン酸亜鉛セメント、酸化型亜鉛−ユージノール系、ヨ
ードホルム系及び高分子系等が用いられている。しかし
ながら、これらの歯科用組成物は歯及び骨の生体組織と
は本質的に異なる材質からなるものである。それ故、生
体組織に対しては化学的又は物理的に接着するにとどま
り、口腔内や生体内で経時的に接着力が低下し、剥離や
破折による充填部内の死腔を多々生じることもある。ま
た、歯科用根管充填材の場合、配合しているユージノー
ルやヨードホルム等の物質が溶出し、刺激性を示すこと
が問題となっている。
2. Description of the Related Art Conventional dental compositions include, for example,
Zinc phosphate cement, oxidized zinc-eugenol system, iodoform system, polymer system and the like are used. However, these dental compositions are composed of materials that are essentially different from the living tissues of teeth and bones. Therefore, it is only chemically or physically adhered to the living tissue, and the adhesive strength is decreased with time in the oral cavity or in the living body, and many dead spaces in the filling part due to peeling or breakage may occur. is there. Further, in the case of a dental root canal filling material, it is a problem that substances such as eugenol and iodoform which are mixed therein are eluted to show irritation.

【0003】一方、自己硬化性リン酸カルシウムは水あ
るいは酸と混和することにより、骨や歯の主成分である
アパタイトに転化し、同時に硬化する。この性質のた
め、生体親和性に優れ、生体組織と容易に同化すること
から、歯科用生体材料に利用することが種々試みられて
いる。
On the other hand, the self-hardening calcium phosphate is converted into apatite which is a main component of bones and teeth by mixing with water or acid, and simultaneously hardens. Due to this property, it has excellent biocompatibility and easily assimilates with living tissue, and therefore various attempts have been made to use it as a dental biomaterial.

【0004】[0004]

【発明が解決しようとする課題】しかしながら、自己硬
化性リン酸カルシウムは、前記の高分子系に比較する
と、作業性が悪いという欠点がある。つまり、水あるい
は酸との練和物が流動性の低い湿り砂状であるため骨欠
損部や歯根管等の狭い箇所又は複雑な形状の場所への充
填が困難である。また、封鎖性が不良であるため治療部
の再感染の原因となることがある。その上、硬化時間が
10分程度であり、歯科用として用いる場合には充填作
業可能な時間が、短いという問題がある。
However, the self-hardening calcium phosphate has a drawback that the workability is poor as compared with the above-mentioned polymer type. That is, since the kneaded product with water or acid is in the form of wet sand with low fluidity, it is difficult to fill a narrow portion such as a bone defect portion or a root canal or a place having a complicated shape. In addition, the poor sealability may cause reinfection of the treatment site. In addition, the curing time is about 10 minutes, and there is a problem that the filling workable time is short when used for dentistry.

【0005】要求される歯科用組成物の特性としては、
作業性、特に流動性及び練和性が良好であり、生体親和
性に優れ、硬化型であり、また充填作業可能な時間の長
いことが挙げられるが、現在、これらの特性をすべて満
足する歯科用組成物はない。リン酸カルシウムとフッ素
化合物を混合し、水あるいは酸で練和したものは、充填
後、アパタイト化し、生体親和性に優れている。しか
し、このものは凝結時間が30分以内であるため(特開
昭63−252913)作業性、流動性が悪く、充填作
業可能な時間が短いという欠点がある。
The characteristics of the required dental composition are:
Workability, especially fluidity and kneading properties are good, biocompatibility is excellent, it is a curable type, and it can be filled for a long time, but at present, dentistry that satisfies all these characteristics There is no composition for use. A mixture of calcium phosphate and a fluorine compound, which is kneaded with water or an acid, becomes apatite after filling and has excellent biocompatibility. However, since this product has a setting time of 30 minutes or less (Japanese Patent Laid-Open No. 63-252913), it has poor workability and fluidity, and has a shortcoming that the workable time is short.

【0006】[0006]

【課題を解決するための手段】本発明者らは、このよう
な歯科用組成物の難点を克服するため鋭意研究を重ねた
結果、リン酸カルシウムとフッ素化合物を混合し、さら
に、重合体微粒子を添加することによって、これらの欠
点を除き、作業性、流動性及び充填作業良好な組成物を
提供しうることを見出したのである。即ち、本発明はリ
ン酸カルシウムとフッ素化合物を含有し、さらに重合体
微粒子を含有することを特徴とする歯科用硬化性組成物
を提供するものである。
Means for Solving the Problems As a result of intensive studies to overcome such difficulties of the dental composition, the present inventors have mixed calcium phosphate with a fluorine compound, and further added polymer fine particles. It was found that by doing so, a composition having good workability, fluidity and filling work can be provided by eliminating these drawbacks. That is, the present invention provides a dental curable composition characterized by containing calcium phosphate and a fluorine compound, and further containing polymer fine particles.

【0007】本発明の組成物は、優れた操作性を示す歯
科用硬化組成物であり、根管充填後、硬化してアパタイ
トに転換し、刺激性もなく、生体親和性に優れた根管充
填材となしうる。
The composition of the present invention is a hardened dental composition exhibiting excellent operability. After being filled with a root canal, it hardens and transforms into apatite, has no irritation, and has excellent biocompatibility. Can be used as a filler.

【0008】以下、本発明を更に詳細に説明する。本発
明に用いられるリン酸カルシウムとしては、α−リン酸
三カルシウム(α−TCP)、リン酸四カルシウム(四
CP)、第二リン酸カルシウム・二水塩(DCPD)更
に、ハイドロキシアパタイト(HAP)、フッ素アパタ
イト(FAP)、β−リン酸三カルシウム(β−TC
P)、第二リン酸カルシウム・無水塩(DCPA)、リ
ン酸八カルシウム(OCP)、第一リン酸カルシウム・
無水塩(MCPA)、第一リン酸カルシウム・一水塩
(MCPM)などがある。これらのリン酸カルシウムの
うち、1種または2種以上を混合して使用する。該リン
酸カルシウムのリンとカルシウムの原子比は1.3〜
2.0(Ca/P)が好ましく、更に好ましくは1.4
〜1.8の範囲が好適である。本発明に用いられるリン
酸カルシウムは通常粉体が用いられ、それは従来歯科用
として用いられるものと特に異ならないが、通常、平均
粒子径0.5〜20μm、好ましくは1〜10μmの範
囲である。
The present invention will be described in more detail below. Examples of calcium phosphate used in the present invention include α-tricalcium phosphate (α-TCP), tetracalcium phosphate (4 CP), dicalcium phosphate dihydrate (DCPD), hydroxyapatite (HAP), and fluoroapatite. (FAP), β-tricalcium phosphate (β-TC
P), dicalcium phosphate anhydrous salt (DCPA), octacalcium phosphate (OCP), monocalcium phosphate
There are anhydrous salts (MCPA), monocalcium phosphate monohydrate (MCPM) and the like. Of these calcium phosphates, one kind or a mixture of two or more kinds is used. The atomic ratio of phosphorus to calcium in the calcium phosphate is 1.3 to
2.0 (Ca / P) is preferable, and 1.4 is more preferable.
The range of to 1.8 is preferable. The calcium phosphate used in the present invention is usually a powder, which is not particularly different from that used conventionally for dentistry, but usually has an average particle size of 0.5 to 20 μm, preferably 1 to 10 μm.

【0009】次にフッ素化合物としては、水に難溶性の
CaF、MgF、NaPOF、BeF、SrF
、BaF、SnF、AlF、水溶性のKF、N
aF、KFHF、NaFHF、NHFHFなどが挙げ
られる。これらのフッ素化合物は、1種または2種以上
を併用して用いることもできるが、特に、CaFが好
ましい。配合量はリン酸カルシウムに対しCa/F(グ
ラムアトム比)1.0〜60が好ましい。このフッ素化
合物は水に難溶性の粉末の場合、通常それは平均粒子径
0.5〜20μm、好ましくは1〜10μmのものが用
いられる。なお、本発明の歯科用硬化組成物が液材と粉
材とからなる場合、このフッ素化合物は液材または粉材
のどちらに混合してもよい。
Next, as the fluorine compound, CaF 2 , MgF 2 , NaPO 3 F, BeF 2 and SrF which are poorly soluble in water are used.
2 , BaF 2 , SnF 2 , AlF 3 , water-soluble KF, N
Examples include aF, KFHF, NaFHF, NH 4 FHF and the like. These fluorine compounds may be used alone or in combination of two or more, and CaF 2 is particularly preferable. The compounding amount is preferably Ca / F (gram atom ratio) of 1.0 to 60 with respect to calcium phosphate. When the fluorine compound is a powder that is poorly soluble in water, it is usually used having an average particle size of 0.5 to 20 μm, preferably 1 to 10 μm. When the dental curing composition of the present invention comprises a liquid material and a powder material, this fluorine compound may be mixed with either the liquid material or the powder material.

【0010】本発明で使用する重合体微粒子とは、不溶
解性である有機系高分子が用いられ、特に製造方法の制
限はないが、一般的に1種もしくは数種のビニル単量
体、架橋性単量体を常法により乳化重合させることによ
り得られる球状の高分子であり、市販のものも使用する
ことができる。
As the polymer fine particles used in the present invention, an insoluble organic polymer is used, and the production method is not particularly limited, but in general, one or several vinyl monomers, It is a spherical polymer obtained by emulsion-polymerizing a crosslinkable monomer by a conventional method, and a commercially available product can also be used.

【0011】本発明に用いる重合体微粒子の平均粒子径
は、0.1〜10μmのものが好ましく、更に好ましく
は0.5〜5.0μm、最も好ましくは1.0〜3.0
μmが好適である。粒子径が0.1μm未満では、流動
性向上に十分な効果が発揮できない。また、10μmを
超えると、水あるいは酸との練和物がざらつき展延性が
減少し、流動性が低下する。
The average particle diameter of the polymer fine particles used in the present invention is preferably 0.1 to 10 μm, more preferably 0.5 to 5.0 μm, and most preferably 1.0 to 3.0.
μm is preferred. If the particle size is less than 0.1 μm, sufficient effect for improving fluidity cannot be exhibited. On the other hand, when it exceeds 10 μm, the kneaded product with water or acid is rough and the spreadability is reduced, so that the fluidity is lowered.

【0012】リン酸カルシウムとフッ素化合物の粉体合
計量に対する重合体微粒子の添加量は、該粉体中0.1
〜20重量%(以下、重量%は特記しない限り%で表
す)が好ましく、更に好ましくは1〜15%である。重
合体微粒子の添加量が0.1%未満では流動性が十分に
向上せず、また充填操作可能な時間も延長することがで
きないので好ましくない。添加量が20%を超えるとリ
ン酸カルシウムの硬化が阻害され、歯科用組成物として
の性能が充分発揮されないので好ましくない。
The amount of polymer fine particles added to the total amount of calcium phosphate and fluorine compound powder is 0.1 in the powder.
-20% by weight (hereinafter,% by weight is represented by% unless otherwise specified) is preferable, and more preferably 1-15%. When the amount of the polymer fine particles added is less than 0.1%, the fluidity is not sufficiently improved, and the time during which the filling operation can be performed cannot be extended, which is not preferable. If the addition amount exceeds 20%, the hardening of calcium phosphate is inhibited and the performance as a dental composition is not sufficiently exhibited, which is not preferable.

【0013】上記重合体の製造に用いるビニル単量体と
しては、スチレン、α−メチルスチレン、アクリル酸、
アクリル酸アルキル、メタクリル酸、メタクリル酸アル
キル、ビニルエステル、ビニルシアン化物及びハロゲン
化ビニル等が挙げられる。
Vinyl monomers used in the production of the above polymers include styrene, α-methylstyrene, acrylic acid,
Examples thereof include alkyl acrylate, methacrylic acid, alkyl methacrylate, vinyl ester, vinyl cyanide and vinyl halide.

【0014】また、架橋性単量体としては、ジビニルベ
ンゼン、エチレングリコール(メタ)アクリレート、ト
リエチロールプロパントリメタクリレート等の不飽和結
合を、一分子中に二つ以上有する単量体が挙げられる。
Examples of the crosslinkable monomer include monomers having two or more unsaturated bonds in one molecule, such as divinylbenzene, ethylene glycol (meth) acrylate, and trimethylolpropane trimethacrylate.

【0015】また、本発明の歯科用硬化組成物では、更
に必要に応じて、X線造影剤を任意に含有させることが
できる。X線造影剤としては、バリウム塩、ビスマス
塩、アルミニウム塩またはヨードホルムから成る群より
1種以上選択することができる。X線造影剤の添加量は
特に限定されないが、リン酸カルシウム粉体に対して
0.1〜50%が好ましい。
Further, the dental curing composition of the present invention may further contain an X-ray contrast agent, if desired. As the X-ray contrast agent, one or more kinds can be selected from the group consisting of barium salt, bismuth salt, aluminum salt and iodoform. The addition amount of the X-ray contrast agent is not particularly limited, but is preferably 0.1 to 50% with respect to the calcium phosphate powder.

【0016】また、本発明の歯科用硬化組成物粉体10
0部に対する水あるいは酸の量は10〜200部が好ま
しく、更に好ましくは、25〜200部が好適である。
10部未満では、ペースト粘度が高すぎて臨床上の操作
性が悪く、硬化時間が早くなるので好ましくない。ま
た、200部を超えるとペースト粘度が低くなり、充填
操作が困難となるので好ましくない。
Further, the dental curing composition powder 10 of the present invention
The amount of water or acid with respect to 0 part is preferably 10 to 200 parts, and more preferably 25 to 200 parts.
If the amount is less than 10 parts, the paste viscosity is too high, the clinical operability is poor, and the curing time is short, which is not preferable. Further, when it exceeds 200 parts, the paste viscosity becomes low and the filling operation becomes difficult, which is not preferable.

【0017】本発明の歯科用硬化組成物には、更には上
記成分に加えて、リンゴ酸、クエン酸等の有機酸または
その塩、pH調整剤、アルミナ、ジルコニア等の生体中
で溶解しない安定なフィラー、またポリカルボン酸やそ
の誘導体及びそれらの塩、多価アルコール、界面活性
剤、CMC−Na等の水溶性高分子物質などの本発明の
効果を損なわない範囲で配合することができる。
In addition to the above-mentioned components, the dental curing composition of the present invention further comprises an organic acid such as malic acid or citric acid or a salt thereof, a pH adjusting agent, alumina, zirconia, etc. It is possible to add various fillers, polycarboxylic acids or derivatives thereof and salts thereof, polyhydric alcohols, surfactants, water-soluble polymer substances such as CMC-Na, etc. within a range that does not impair the effects of the present invention.

【0018】本発明の歯科用硬化組成物は、上記成分を
混合したものを使用時に水に溶解、懸濁するようにして
もよく、或いは、粉材と水可溶性成分を予め水に溶解し
た液材との形態とし、使用時にこれら粉材と液材とを練
和するようにしてもよい。
The dental hardening composition of the present invention may be prepared by dissolving and suspending a mixture of the above components in water at the time of use, or a liquid prepared by previously dissolving a powder material and a water-soluble component in water. Alternatively, the powder material and the liquid material may be kneaded when used.

【0019】[0019]

【実施例】以下、本発明を実施例と比較例を示し、具体
的に説明するが、下記の実施例に制限されるものでな
い。以下、組成を示す部及び%は特記しない限り重量部
及び重量%を表す。 実施例1 攪拌機、温度計、還流コンデンサー付のセパラブルフラ
スコに、水20部、ラウリル硫酸ナトリウム0.01部
を仕込み、攪拌下に、窒素置換しながら70℃迄昇温し
た。内温を70℃に保ち、重合開始剤として過硫酸カリ
ウム2部を添加し、溶解後、スチレン2部、メタクリル
酸メチル、ジビニルベンゼン各0.01部の混合モノマ
ーを仕込み、3時間反応させた。反応終了後、引き続
き、予め、水200部、ラウリル硫酸ナトリウム1.5
部にスチレン297部、メタクリル酸メチル3部、ジビ
ニルベンゼン12部の混合モノマーを攪拌下に加えて作
成しておいた単量体混合の乳化液を連続的に4時間で添
加し、反応を行った。添加終了後、更に4時間の熟成を
行いエマルションを得た。該エマルションを常温までに
冷却し、8%アンモニウム水にて中和し、pHを8.5
に調整した。こうして得られたエマルション220部、
水270部と過硫酸アンモニウム2gの存在下で、スチ
レン300部とジビニルベンゼン12部を水200部と
乳化し重合した。その後、スプレードライヤーにて、乾
燥させ、平均粒子径1.0μmの重合体微粒子を得た。
EXAMPLES The present invention will be specifically described below by showing Examples and Comparative Examples, but the invention is not limited to the following Examples. Hereinafter, parts and% indicating the composition represent parts by weight and% by weight, unless otherwise specified. Example 1 A separable flask equipped with a stirrer, a thermometer, and a reflux condenser was charged with 20 parts of water and 0.01 part of sodium lauryl sulfate, and the temperature was raised to 70 ° C. under nitrogen with stirring. The internal temperature was maintained at 70 ° C., 2 parts of potassium persulfate was added as a polymerization initiator, and after dissolution, a mixed monomer of 2 parts of styrene, 0.01 parts of methyl methacrylate and 0.01 part of divinylbenzene was charged and reacted for 3 hours. . After completion of the reaction, 200 parts of water and 1.5 parts of sodium lauryl sulfate were previously prepared.
297 parts of styrene, 3 parts of methyl methacrylate, and 12 parts of divinylbenzene were added under stirring to the emulsion to prepare a monomer mixture, which was continuously added for 4 hours to carry out the reaction. It was After the addition was completed, aging was performed for 4 hours to obtain an emulsion. The emulsion was cooled to room temperature, neutralized with 8% ammonium water, and adjusted to pH 8.5.
Adjusted to. 220 parts of the emulsion thus obtained,
300 parts of styrene and 12 parts of divinylbenzene were emulsified and polymerized with 200 parts of water in the presence of 270 parts of water and 2 g of ammonium persulfate. Then, it was dried with a spray dryer to obtain polymer fine particles having an average particle diameter of 1.0 μm.

【0020】このようにして得られた重合体微粒子を用
いて下記試験を行った。α−TCP(平均粒子径3.5
μm)にCaF(平均粒子径2μm)を0.1mol
/molα−TCPの割合で加えた混合物に、上記で得
た重合体微粒子を10%攪拌、混合して歯科用組成物を
得た。該歯科用組成物1gにpH5.0の0.2Mクエ
ン酸溶液(NaOH、KOHの混合液によりpH調整を
した)を0.40ml加え、練和し、ペーストを得た。
このペーストについて、以下の試験を行った。その結果
を、表1に示す。
The following tests were carried out using the polymer fine particles thus obtained. α-TCP (average particle size 3.5
0.1 mol of CaF 2 (average particle size 2 μm)
The polymer fine particles obtained above were stirred and mixed by 10% into the mixture added at a ratio of / mol α-TCP to obtain a dental composition. To 1 g of the dental composition, 0.40 ml of a 0.2 M citric acid solution having a pH of 5.0 (pH was adjusted with a mixed solution of NaOH and KOH) was added and kneaded to obtain a paste.
The following tests were performed on this paste. The results are shown in Table 1.

【0021】該ペーストの評価は下記試験法に従って行
った。 練和性評価 練和開始後、1分でペースト状となったものを練和性良
好と判断した。また、ペーストを得るために、1分より
長い練和が必要なものを不良とした。 流動性(フロー)試験 ADA No.57 練和ペーストを0.5ml取り、約20gのガラス板上
に乗せた。練和開始3分後に該ペーストの上にもう一枚
の上記と同じガラス板を乗せ、さらに静かに100gの
分銅を乗せた。練和開始10分後に重りを外し、ペース
トの広がりを最大、最小直径の平均値として算出し、こ
れをフロー値とした。この値の大きいものほど流動性良
好と判断した。 流動性・10分後 練和ペーストを0.5ml取り、約20gのガラス板上
に乗せた。練和開始10分後に該ペーストの上にもう一
枚の上記と同じガラス板を乗せ、さらに静かに100g
の分銅を乗せた。練和開始17分後に重りを外し、ペー
ストの広がりを最大、最小直径の平均値として算出し
た。この値の大きいものほど流動性良好と判断した。 硬化試験 練和開始2分後のペーストを内径10mm、高さ2mm
のリングに満たし、37℃、相対湿度95%以上の恒温
槽に入れ、その後、荷重100g、直径2mmのギルモ
ア針の圧痕がつかなくなった時間を硬化時間とした。硬
化時間が30〜240分の範囲のものを操作可能な時間
が適当であると判断した。 アパタイト化試験 硬化性を評価した検体を37℃の水中に一週間浸漬し
た。検体を取り出し乾燥した後、瑪瑙乳鉢で粉砕した。
更に、内部標準として20重量%酸化チタンを瑪瑙乳鉢
で充分混合し、α−TCP2θ30.7°の回折強度と
酸化チタン2θ27.5°のピーク強度比より、α−T
CPの残存量から逆算してアパタイト転換量(HA化
度)とした。 封鎖性試験 抜去歯の歯冠部と根管部分を切除し、歯根部を仮封材を
用いて封鎖した。この抜去歯の根管部分にペーストを充
填し硬化した後、根尖部のみ墨汁中に浸漬した。これ
を、37℃、24時間で保存した後、鋭利な刃を用いて
象牙細管の走向に切断し、根尖部よりの墨汁の侵入比率
を測定した。この侵入比率は根管の長さに対する侵入部
分の長さの比率で表し、この値の小さいものほど封鎖性
良好と判断した。
The paste was evaluated according to the following test methods. Kneadability evaluation A paste-like product that was formed in 1 minute after the start of kneading was judged to have good kneadability. In addition, those requiring kneading for more than 1 minute in order to obtain the paste were regarded as defective. Fluidity (flow) test ADA No. 57 0.5 ml of the kneading paste was taken and placed on a glass plate of about 20 g. After 3 minutes from the start of kneading, another glass plate as above was placed on the paste, and a weight of 100 g was gently placed. Ten minutes after the start of kneading, the weight was removed, and the spread of the paste was calculated as the average value of the maximum and minimum diameters, which was taken as the flow value. The larger the value, the better the fluidity. Flowability-After 10 minutes 0.5 ml of the kneading paste was taken and placed on a glass plate of about 20 g. Ten minutes after the start of kneading, put another glass plate as above on the paste, and gently quietly 100 g.
I put the weight of. The weight was removed 17 minutes after the start of kneading, and the spread of the paste was calculated as the average value of the maximum and minimum diameters. The larger the value, the better the fluidity. Curing test 2 minutes after the start of kneading, paste with an inner diameter of 10 mm and a height of 2 mm
Was filled in a constant temperature bath at 37 ° C. and a relative humidity of 95% or more, and then the time when the indentation of a Gilmore needle having a load of 100 g and a diameter of 2 mm was not formed was defined as the curing time. It was judged that the one having a curing time in the range of 30 to 240 minutes was suitable for the operable time. Apatite-forming test The specimen evaluated for curability was immersed in water at 37 ° C for one week. The sample was taken out, dried, and then crushed in an agate mortar.
Furthermore, as an internal standard, 20% by weight titanium oxide was thoroughly mixed in an agate mortar, and from the ratio of the diffraction intensity of α-TCP2θ30.7 ° and the peak intensity of titanium oxide 2θ27.5 °, α-T
The amount of conversion of apatite (degree of HA conversion) was calculated back from the amount of residual CP. Sealing test The crowns and root canals of the extracted teeth were excised, and the roots were sealed using a temporary sealing material. The root canal portion of the extracted tooth was filled with paste and hardened, and then only the root apex was immersed in ink. After this was stored at 37 ° C. for 24 hours, it was cut into the dentinal tubules using a sharp blade, and the penetration ratio of ink from the apex was measured. This invasion ratio was expressed by the ratio of the length of the invading part to the length of the root canal, and the smaller the value, the better the sealing performance.

【0022】実施例2 実施例1の製造方法に従って、平均粒子径1.8μmの
重合体微粒子を製造した。該重合体微粒子を用いて、実
施例1と同一条件で行った。その結果を、表1に示す。
Example 2 According to the production method of Example 1, polymer fine particles having an average particle diameter of 1.8 μm were produced. The same procedure as in Example 1 was carried out using the polymer fine particles. The results are shown in Table 1.

【0023】実施例3 実施例1の重合体微粒子を、市販のテクポリマーMB−
4C(ポリメタクリル酸メチル真球状微粒子、平均粒子
径4μm、積水化成品工業株式会社製)に置き換え、実
施例1と同一条件で行った。その結果を、表1に示す。
Example 3 The polymer fine particles of Example 1 were mixed with commercially available Techpolymer MB-
4C (polymethylmethacrylate true spherical particles, average particle size 4 μm, manufactured by Sekisui Plastics Co., Ltd.), and the same conditions as in Example 1 were used. The results are shown in Table 1.

【0024】実施例4 実施例1のα−TCPを、α−TCPと第二リン酸カル
シウム・二水塩(DCPD、平均粒子径6μm)の等モ
ルの混合物に置き換え、実施例1と同一条件で行った。
その結果を、表1に示す。
Example 4 The same procedure as in Example 1 was carried out by replacing α-TCP of Example 1 with an equimolar mixture of α-TCP and dicalcium phosphate dihydrate (DCPD, average particle size 6 μm). It was
The results are shown in Table 1.

【0025】実施例5 実施例1のα−TCPを、リン酸四カルシウム(四C
P、平均粒子径5μm)に置き換え、実施例1と同一条
件で行った。その結果を、表1に示す。
Example 5 The α-TCP of Example 1 was mixed with tetracalcium phosphate (tetra-C).
P, average particle size 5 μm), and the same conditions as in Example 1 were used. The results are shown in Table 1.

【0024】実施例6 実施例1のα−TCPを、第二リン酸カルシウム・二水
塩(DCPD、平均粒子径6μm)に置き換え、実施例
1と同一条件で行った。その結果を、表1に示す。
Example 6 α-TCP of Example 1 was replaced with dicalcium phosphate dihydrate (DCPD, average particle size 6 μm), and the same conditions as in Example 1 were used. The results are shown in Table 1.

【0026】実施例7 実施例1のCaFを、CaFとNHF・HFとの
混合物に置き換え試験を行った。CaF0.13mo
l/molα−TCP、NHF・HF0.2mol/
molα−TCPの割合で加えた。以下は実施例1と同
一条件で行った。その結果を、表1に示す。
Example 7 A test was conducted by replacing CaF 2 of Example 1 with a mixture of CaF 2 and NH 4 F.HF. CaF 2 0.13mo
1 / mol α-TCP, NH 4 F · HF 0.2 mol /
It was added in the proportion of mol α-TCP. The following was performed under the same conditions as in Example 1. The results are shown in Table 1.

【0027】実施例8 実施例1のCaFを、KFに0.2Mクエン酸溶液を
1.2Mクエン酸溶液置き換え、実施例1と同一条件で
行った。その結果を表1に示す。
Example 8 CaF 2 of Example 1 was replaced with KF by replacing a 0.2M citric acid solution with a 1.2M citric acid solution, and carrying out the same conditions as in Example 1. The results are shown in Table 1.

【0028】実施例9 実施例1のCaFを、SrF(平均粒子径2μm)
とNaFの等モル混合物に、0.2Mクエン酸溶液を
1.2Mクエン酸溶液置き換え、実施例1と同一条件で
行った。その結果を表1に示す。
Example 9 CaF 2 of Example 1 was mixed with SrF 2 (average particle size 2 μm).
A 0.2M citric acid solution was replaced with a 1.2M citric acid solution in an equimolar mixture of NaF and NaF, and the same conditions as in Example 1 were used. The results are shown in Table 1.

【0029】実施例10 実施例1のα−TCPを、α−TCPと第二リン酸カル
シウム・二水塩(DCPD(,平均粒子径3μm))の
等モルの混合物に置き換え、実施例3で用いた市販のテ
クポリマーMB−4C(平均粒子径4μm積水化成品工
業株式会社製)に置き換え、実施例1と同一条件で行っ
た。その結果を、表1に示す。
Example 10 The α-TCP of Example 1 was replaced with an equimolar mixture of α-TCP and dicalcium phosphate dihydrate (DCPD (, average particle size 3 μm)), and used in Example 3. The commercially available techpolymer MB-4C (average particle size: 4 μm, manufactured by Sekisui Plastics Co., Ltd.) was used, and the same conditions as in Example 1 were used. The results are shown in Table 1.

【0030】実施例11 実施例1のCaFを除き、0.2Mクエン酸溶液を
1.0Mクエン酸溶液と1.5KFよりなる液に置き換
え、実施例1と同一条件で行った。その結果を表1に示
す。
Example 11 The procedure was carried out under the same conditions as in Example 1 except that CaF 2 in Example 1 was removed and the 0.2 M citric acid solution was replaced with a solution containing 1.0 M citric acid solution and 1.5 KF. The results are shown in Table 1.

【0031】実施例12 α−TCPにCaFを0.1mol/molα−TC
Pの割合で加えた混合物70部に硫酸バリウム15部
(平均粒子径1.5μm)、次炭酸ビスマス20部(平
均粒子径1.1μm)、実施例1の重合体微粒子10部
を撹拌、混合して歯科用組成物を得た。この歯科用組成
物1gをpH6.0の1.2Mクエン酸溶液を(NaO
H、KOHの混合液によりpH調整した。)を0.4m
l加え、練和し、ペースト得た。このペーストについ
て、実施例1と同一条件で行った。その結果を、表1に
示す。
Example 12 α-TCP with CaF 2 0.1 mol / mol α-TC
To 70 parts of the mixture added in the proportion of P, 15 parts of barium sulfate (average particle size 1.5 μm), 20 parts of bismuth subcarbonate (average particle size 1.1 μm), and 10 parts of the polymer fine particles of Example 1 were stirred and mixed. Then, a dental composition was obtained. 1 g of this dental composition was added to a 1.2 M citric acid solution having a pH of 6.0 (NaO 2).
The pH was adjusted with a mixed solution of H and KOH. ) 0.4m
l was added and kneaded to obtain a paste. This paste was applied under the same conditions as in Example 1. The results are shown in Table 1.

【0032】比較例1 重合体微粒子を除いた他は、実施例1と同一条件で行っ
た。結果を、表1に示す。
Comparative Example 1 The same conditions as in Example 1 were used except that the polymer fine particles were removed. The results are shown in Table 1.

【0033】比較例2 実施例1のα−TCPを、α−TCPと第二リン酸カル
シウム・二水塩(DCPD(,平均粒子径3.5μ
m))の等モルの混合物に置き換え、重合体微粒子を除
いた他は、実施例1と同一条件で行った。結果を、表1
に示す。
Comparative Example 2 α-TCP of Example 1 was prepared by converting α-TCP and dicalcium phosphate dihydrate (DCPD (, average particle size 3.5 μm
m)) was replaced with an equimolar mixture and the polymer fine particles were removed, and the same conditions as in Example 1 were used. The results are shown in Table 1.
Shown in.

【0034】比較例3 実施例1のCaFを、CaFとNHF・HFとの
混合物に置き換え、重合体微粒子を除き試験を行った。
CaF0.13mol/molα−TCP、NH
・HF0.2mol/molα−TCPの割合で加え
た。以下は実施例1と同一条件で行った。その結果を、
表1に示す。
Comparative Example 3 CaF 2 of Example 1 was replaced with a mixture of CaF 2 and NH 4 F.HF, and polymer fine particles were removed, and a test was conducted.
CaF 2 0.13 mol / mol α-TCP, NH 4 F
-HF was added at a ratio of 0.2 mol / mol α-TCP. The following was performed under the same conditions as in Example 1. The result is
It shows in Table 1.

【0035】比較例4 実施例1のCaFを除いた他は、実施例1と同一条件
で行った。その結果を、表1に示す。
Comparative Example 4 The same conditions as in Example 1 were used except that CaF 2 in Example 1 was omitted. The results are shown in Table 1.

【0036】[0036]

【表1】 [Table 1]

【0037】[0037]

【発明の効果】本発明の歯科用硬化性組成物は、重合体
微粒子を添加することにより、根管等の狭い箇所又は複
雑な形状の部分に充填されるに充分な流動性を有し、操
作可能な時間も延長した。また、該組成物は、生体中で
適度な時間で完全に硬化し、更にリン酸カルシウムがフ
ッ素化アパタイトに転換するため、生体中で極めて安定
であり、刺激も全くなく、生体親和性に優れており、歯
科用根管充填材、骨補填材等の生体材料としても好適で
ある。
EFFECT OF THE INVENTION The dental curable composition of the present invention has sufficient fluidity to be added to a narrow portion such as a root canal or a portion having a complicated shape by adding polymer fine particles, The operation time has also been extended. Further, the composition is completely hardened in a suitable time in a living body, and since calcium phosphate is further converted into fluorinated apatite, it is extremely stable in a living body, has no irritation, and has excellent biocompatibility. It is also suitable as a biomaterial such as a dental root canal filling material and a bone filling material.

───────────────────────────────────────────────────── フロントページの続き (72)発明者 西辻 俊彦 山口県下関市彦島迫町七丁目1番1号 三 井東圧化学株式会社内 (72)発明者 落合 良仁 神奈川県藤沢市本藤沢3−3−7 (72)発明者 斉藤 浩一 神奈川県中郡二宮町山西457 ライオン株 式会社二宮寮 (72)発明者 大里 文夫 神奈川県中郡二宮町山西457 ライオン株 式会社二宮寮 ─────────────────────────────────────────────────── ─── Continuation of the front page (72) Inventor Toshihiko Nishitsuji 7-1, 1-1 Hikoshimasako-cho, Shimonoseki-shi, Yamaguchi Mitsui Toatsu Chemical Co., Ltd. (72) Inhito Yoshihito 3-3 Motofujisawa, Fujisawa-shi, Kanagawa -7 (72) Inventor Koichi Saito 457 Yamanishi, Ninomiya-cho, Naka-gun, Kanagawa Lion Ninomiya Dormitory (72) Inventor Fumio Osato 457 Yamanishi, Ninomiya-cho, Naka-gun Kanagawa Prefecture Ninomiya Dormitory, Ltd.

Claims (4)

【特許請求の範囲】[Claims] 【請求項1】 リン酸カルシウムとフッ素化合物を含有
し、さらに重合体微粒子を含有することを特徴とする歯
科用硬化性組成物。
1. A dental curable composition comprising calcium phosphate and a fluorine compound, and further containing polymer fine particles.
【請求項2】 重合体微粒子の平均粒子径が0.1〜1
0μmである請求項1記載の組成物。
2. The polymer fine particles have an average particle size of 0.1 to 1.
The composition according to claim 1, which is 0 μm.
【請求項3】 リン酸カルシウムの原子比(Ca/P)
が1.3〜2.0である請求項1記載の組成物。
3. Atomic ratio of calcium phosphate (Ca / P)
Is 1.3 to 2.0.
【請求項4】 リン酸カルシウムがα−リン酸三カルシ
ウムを含有する請求項1記載の組成物。
4. The composition according to claim 1, wherein the calcium phosphate contains α-tricalcium phosphate.
JP6146972A 1993-08-10 1994-06-07 Curable composition for dental use Pending JPH07101817A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP6146972A JPH07101817A (en) 1993-08-10 1994-06-07 Curable composition for dental use

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP21685393 1993-08-10
JP5-216853 1993-08-10
JP6146972A JPH07101817A (en) 1993-08-10 1994-06-07 Curable composition for dental use

Publications (1)

Publication Number Publication Date
JPH07101817A true JPH07101817A (en) 1995-04-18

Family

ID=26477655

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6146972A Pending JPH07101817A (en) 1993-08-10 1994-06-07 Curable composition for dental use

Country Status (1)

Country Link
JP (1) JPH07101817A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2378383A (en) * 2001-06-06 2003-02-12 Gursharan Moonga Nasal delivery of pharmaceutical compositions in powder form

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2378383A (en) * 2001-06-06 2003-02-12 Gursharan Moonga Nasal delivery of pharmaceutical compositions in powder form

Similar Documents

Publication Publication Date Title
Komath et al. Development of a fully injectable calcium phosphate cement for orthopedic and dental applications
US5925715A (en) Photocurable ionomer cement systems
JP4132806B2 (en) Dental paste glass ionomer cement composition
EP1878418B1 (en) Dental Cement
JP2003518989A (en) Bioactive bone cement for osteoporosis
JP2005524682A (en) Medical composition containing ionic salt
JPH0243721B2 (en)
JPH07101817A (en) Curable composition for dental use
JP2001354509A (en) Glass powder for glass ionomer cement
Bhatia et al. Comparative evaluation of a bioactive restorative material with resin modified glass ionomer for calcium-ion release and shear bond strength to dentin of primary teeth-an in vitro study
JP3965249B2 (en) Calcium phosphate cement and calcium phosphate cement composition
JP2742814B2 (en) Root canal filling material
WO2021132707A1 (en) Paste-like composition for dental use, and method for producing the same
JPH0782114A (en) Dental hardening composition
JPH06172008A (en) Hardenable composition
JP2754245B2 (en) Root canal filling material
JP2751939B2 (en) Implant material and method for producing the same
JPH0585914A (en) Curing type paste material
JPH0776507A (en) Dental curing composition
JPH059383B2 (en)
JP2544073B2 (en) Medical and dental hardening cement
JPH02250811A (en) Dental cement composition
JP2008019246A (en) Dental cement
JPH06219917A (en) Dental hardenable composition
JP2644082B2 (en) Medical and dental curable materials